Treatment With the Radiolabeled Somatostatin Analog [ ¹⁷⁷ Lu-DOTA ⁰ ,Tyr ³ ]Octreotate: Toxicity, Efficacy, and Survival

Abstract

Treatment with [(177)Lu-DOTA(0),Tyr(3)]octreotate has few adverse effects. Tumor response rates and progression-free survival compare favorably to the limited number of alternative treatment modalities. Compared with historical controls, there is a benefit in OS from time of diagnosis of several years.